HISHAM KORRAA: Open Payments
NPI 1225151202 · NEWPORT BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,724 in 44 payments from 11 companies in 2025. Trend: 2023 $2,318 · 2024 $2,145 · 2025 $1,724
Food & beverage: $1,724
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $379 |
| Axsome Therapeutics, Inc. | 4 | $353 |
| Teva Pharmaceuticals USA, Inc. | 3 | $323 |
| ABBVIE INC. | 6 | $303 |
| Alkermes, Inc. | 3 | $178 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $49 |
| Bausch Health US, LLC | 2 | $48 |
| E.R. Squibb & Sons, L.L.C. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
Products named: CAPLYTA, Auvelity, VRAYLAR, UZEDY, ARISTADA, APLENZIN, COBENFY, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
